User login
Article Type
Changed
Tue, 02/14/2023 - 13:05
Also today, from MDedge Pediatrics, a consult on influenza and pneumonia, brodalumab beats ustekinumab to PASI 100, and a novel agent cuts LDL in patients who are intolerant to statins.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify
Publications
Topics
Sections
Also today, from MDedge Pediatrics, a consult on influenza and pneumonia, brodalumab beats ustekinumab to PASI 100, and a novel agent cuts LDL in patients who are intolerant to statins.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify
Also today, from MDedge Pediatrics, a consult on influenza and pneumonia, brodalumab beats ustekinumab to PASI 100, and a novel agent cuts LDL in patients who are intolerant to statins.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica